FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119612879> ?p ?o ?g. }

• W2119612879 endingPage "624" @default.
• W2119612879 startingPage "617" @default.
• W2119612879 abstract "HepatologyVolume 34, Issue 4 p. 617-624 Concise ReviewFree Access Hepatitis B e antigen–negative chronic hepatitis B Stephanos J. Hadziyannis M.D., Corresponding Author Stephanos J. Hadziyannis M.D. [email protected] Academic Department of Medicine, University of Athens School of Medicine, Hippokration General Hospital, Athens, Greece; and the Department of Medicine of Henry Dynan Hospital, Athens, Greece.Academic Department of Medicine, University of Athens School of Medicine, Hippokration General Hospital, 114 Vas. Sophias Ave., 115 27 Athens, Greece.fax: (3) 1-7706871===Search for more papers by this authorDimitrios Vassilopoulos, Dimitrios Vassilopoulos Academic Department of Medicine, University of Athens School of Medicine, Hippokration General Hospital, Athens, Greece; and the Department of Medicine of Henry Dynan Hospital, Athens, Greece.Search for more papers by this author Stephanos J. Hadziyannis M.D., Corresponding Author Stephanos J. Hadziyannis M.D. [email protected] Academic Department of Medicine, University of Athens School of Medicine, Hippokration General Hospital, Athens, Greece; and the Department of Medicine of Henry Dynan Hospital, Athens, Greece.Academic Department of Medicine, University of Athens School of Medicine, Hippokration General Hospital, 114 Vas. Sophias Ave., 115 27 Athens, Greece.fax: (3) 1-7706871===Search for more papers by this authorDimitrios Vassilopoulos, Dimitrios Vassilopoulos Academic Department of Medicine, University of Athens School of Medicine, Hippokration General Hospital, Athens, Greece; and the Department of Medicine of Henry Dynan Hospital, Athens, Greece.Search for more papers by this author First published: 30 December 2003 https://doi.org/10.1053/jhep.2001.27834Citations: 377AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat References 1 Hoofnagle JH. Type B hepatitis: virology, serology and clinical course. Semin Liver Dis 1981; 1: 7– 14.MEDLINE 2 Sherlock S, Thomas HC. Hepatitis B virus infection: the impact of molecular biology. Hepatology 1983; 3: 455– 456.MEDLINE 3 Schalm SW, Thomas HC, Hadziyannis SJ. Chronic hepatitis B. Prog Liver Dis 1990; 9: 443– 462.MEDLINE 4 Hadziyannis SJ. Anti-HBe positive chronic active hepatitis. In: W Szmuness, H Alter, J Maynard, eds. Viral Hepatitis International Symposium. New York: The Franklin Institute Press, 1981; 683. 5 Bonino F, Hoyer B, Nelson J, Engle R, Verme G, Gerin J. Hepatitis B virus DNA in the sera of HBsAg carriers: a marker of active hepatitis B virus replication in the liver. Hepatology 1981; 1: 386– 391.MEDLINE 6 Brechot C, Hadchouel M, Scotto J, Degos F, Charnay P, Trepo C, Tiollais P. Detection of hepatitis B virus DNA in liver and serum: a direct appraisal of the chronic carrier state. Lancet 1981; 2: 765– 768.MEDLINE 7 Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg Vs. anti-HBe positive carriers of hepatitis B virus. Hepatology 1983; 3: 656– 662.MEDLINE 8 Brunetto MR, Stemler M, Rizzetto H, Verme G, Will H, Bonino F. A HBV variant is responsible for anti-HBe positive hepatitis B [Abstract]. J Hepatol 1989; 9: S11. 9 Carman W, Jacyna MR, Karayiannis P, Hadziyannis SJ, Thomas HC. Point mutations in the pre-core regions of HBV in anti-HBe positive patients with chronic hepatitis and persistent HBV replication [Abstract]. J Hepatol 1989; 9: S18. 10 Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588– 591.MEDLINE 11 Brunetto MR, Stemler M, Bonino F, Schodel F, Oliveri F, Rizzetto M, Verme G, et al. A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. J Hepatol 1990; 10: 258– 261.MEDLINE 12 Hadziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepat Rev 1995; 1: 7– 36. 13 Miyakawa Y, Okamoto H, Mayumi M. The molecular basis of hepatitis B e antigen (HBeAg)-negative infections. J Viral Hepat 1997; 4: 1– 8.MEDLINE 14 Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000; 31: 1037– 1044.MEDLINE 15 Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847– 851.MEDLINE 16 Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, Kleiner DE, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000; 32: 828– 834.MEDLINE 17 Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to lamivudine. J Med Virol 2000; 61: 398– 402.MEDLINE 18 Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000; 32: 300– 306.MEDLINE 19 Lok A, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: summary recommendations of a workshop. Gastroenterology 2001; 120: 1828– 1853.MEDLINE 20 Maddrey WC. Hepatitis B: an important public health issue. J Med Virol 2000; 61: 362– 366.MEDLINE 21 Lok AS, Lai CL, Wu PC, Leung EK, Lam TS. Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 1839– 1843.MEDLINE 22 Knoll A, Rohrhofer A, Kochanowski B, Wurm EM, Jilg W. Prevalence of precore mutants in anti-HBe-positive hepatitis B virus carriers in Germany. J Med Virol 1999; 59: 14– 18.MEDLINE 23 Chan HL, Leung NW, Hussain M, Wong ML, Lok AS. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 763– 768.MEDLINE 24 Chowdhury A, Santra A, Chaudhuri S, Ghosh A, Banerjee P, Mazumder DN. Prevalence of hepatitis B infection in the general population: a rural community based study. Trop Gastroenterol 1999; 20: 75– 77.MEDLINE 25 Madzime S, Adem M, Mahomed K, Woelk GB, Mudzamiri S, Williams MA. Hepatitis B virus infection among pregnant women delivering at Harare Maternity Hospital, Harare, Zimbabwe, 1996 to 1997. Cent Afr J Med 1999; 45: 195– 198.MEDLINE 26 Minuk GY, Orr PS, Brown R, Macdonald S, Chaudhary RK, Temple P. Pre-core mutant infections in the Canadian Inuit. J Hepatol 2000; 33: 781– 784.MEDLINE 27 Chu CM, Liaw YF. Natural history of chronic hepatitis B virus infection: an immunopathological study. J Gastroenterol Hepatol 1997; 12: S218– S222.MEDLINE 28 Oketani M, Oketani K, Xiaohong C, Arima T. Low level wild-type and pre-core mutant hepatitis B viruses and HBeAg negative reactivation of chronic hepatitis B. J Med Virol 1999; 58: 332– 337.MEDLINE 29 Li JS, Tong SP, Wen YM, Vitvitski L, Zhang Q, Trepo C. Hepatitis B virus genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. J Virol 1993; 67: 5402– 5410.MEDLINE 30 Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus—large-scale analysis using a new genotyping method. J Infect Dis 1997; 175: 1285– 1293.MEDLINE 31 Laras A, Koskinas J, Avgidis K, Hadziyannis SJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepat 1998; 5: 241– 248.MEDLINE 32 Grandjacques C, Pradat P, Stuyver L, Chevallier M, Chevallier P, Pichoud C, Maisonnas M, et al. Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. J Hepatol 2000; 33: 430– 439.MEDLINE 33 Cabrerizo M, Bartolome J, Inigo ER, Lopez-Alcorocho JM, Cotonat T, Carreno V. Analysis of the hepatitis B virus precore and ORF-X sequences in patients with antibody to hepatitis B e antigen with and without normal ALT levels. J Med Virol 1998; 56: 294– 299.MEDLINE 34 Triki H, Ben Slimane S, Ben Mami N, Sakka T, Ben Ammar A, Dellagi K. High circulation of hepatitis B virus (HBV) precore mutants in Tunisia, North Africa. Epidemiol Infect 2000; 125: 169– 174.MEDLINE 35 Bozdayi AM, Bozkaya H, Turkyilmaz A, Aslan N, Verdi H, Kence A, Uzunalimoglu O. Polymorphism of precore region of hepatitis B virus DNA among patients with chronic HBV infection in Turkey. Infection 1999; 27: 357– 360.MEDLINE 36 Ballard AL, Boxall EH. Epidemiology of precore mutants of hepatitis B in the United Kingdom. J Med Virol 2000; 62: 463– 470.MEDLINE 37 Langer BC, Frosner GG, von Brunn A. Epidemiological study of viral hepatitis types A, B, C, D and E among Inuits in West Greenland. J Viral Hepat 1997; 4: 339– 349.MEDLINE 38 Chan HL, Hussain M, Lok AS. Different hepatitis B virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion. Hepatology 1999; 29: 976– 984.MEDLINE 39 Theamboonlers A, Tangkijvanich P, Jantaradsamee P, Hirsch P, Poovorawan Y. Prevalence of core promoter and precore mutants of hepatitis B virus in Thailand by RFLP and sequencing. Southeast Asian J Trop Med Public Health 1999; 30: 750– 755.MEDLINE 40 Chan HL, Hui Y, Leung NW, Ching JY, Chan FK, Sung JJ. Risk factors for active liver disease in HBeAg-negative chronic hepatitis B virus-infected patients. Am J Gastroenterol 2000; 95: 3547– 3551.MEDLINE 41 Cote PJ, Korba BE, Miller RH, Jacob JR, Baldwin BH, Hornbuckle WE, Purcell RH, et al. Effects of age and viral determinants on chronicity as an outcome of experimental woodchuck hepatitis virus infection. Hepatology 2000; 31: 190– 200.MEDLINE 42 The Incident Investigation Teams. Transmission of hepatitis B to patients from four infected surgeons without hepatitis B e antigen. N Engl J Med 1997; 336: 178– 184.MEDLINE 43 Carman WF, Fagan EA, Hadziyannis S, Karayiannis P, Tassopoulos NC, Williams R, Thomas HC. Association of a precore genomic variant of hepatitis B virus with fulminant hepatitis. Hepatology 1991; 14: 219– 222.MEDLINE 44 Chang MH, Hsu HY, Ni YH, Tsai KS, Lee PI, Chen PJ, Hsu YL, et al. Precore stop codon mutant in chronic hepatitis B virus infection in children: its relation to hepatitis B e seroconversion and maternal hepatitis B surface antigen. J Hepatol 1998; 28: 915– 922.MEDLINE 45 Milich DR, Chen MK, Hughes JL, Jones JE. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998; 160: 2013– 2021.MEDLINE 46 Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci U S A 1990; 87: 6599– 6603.MEDLINE 47 Wang JS, Zhu QR. Infection of the fetus with hepatitis B e antigen via the placenta [letter]. Lancet 2000; 355: 989.MEDLINE 48 Milich DR, Schodel F, Hughes JL, Jones JE, Peterson DL. The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype. J Virol 1997; 71: 2192– 2201.MEDLINE 49 Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733– 1745.MEDLINE 50 Maruyama T, Mitsui H, Maekawa H, Yamada H, Hirayama M, Iino S, Yasuda K, et al. Emergence of the precore mutant late in chronic hepatitis B infection correlates with the severity of liver injury and mutations in the core region. Am J Gastroenterol 2000; 95: 2894– 2904.MEDLINE 51 Zhang YY, Summers J. Enrichment of a precore-minus mutant of duck hepatitis B virus in experimental mixed infections. J Virol 1999; 73: 3616– 3622.MEDLINE 52 Bozkaya H, Akarca US, Ayola B, Lok AS. High degree of conservation in the hepatitis B virus core gene during the immune tolerant phase in perinatally acquired chronic hepatitis B virus infection. J Hepatol 1997; 26: 508– 516.MEDLINE 53 Akarca US, Lok AS. Naturally occurring hepatitis B virus core gene mutations. Hepatology 1995; 22: 50– 60.MEDLINE 54 Hannoun C, Horal P, Lindh M. Long-term mutation rates in the hepatitis B virus genome. J Gen Virol 2000; 81 Pt 1: 75– 83. 55 Fujiwara K, Yokosuka O, Ehata T, Chuang WL, Imazeki F, Saisho H, Omata M. The two different states of hepatitis B virus DNA in asymptomatic carriers: HBe-antigen-positive versus anti-HBe-positive asymptomatic carriers. Dig Dis Sci 1998; 43: 368– 376.MEDLINE 56 Baumeister MA, Medina-Selby A, Coit D, Nguyen S, George-Nascimento C, Gyenes A, Valenzuela P, et al. Hepatitis B virus e antigen specific epitopes and limitations of commercial anti-HBe immunoassays. J Med Virol 2000; 60: 256– 263.MEDLINE 57 Maruyama T, Iino S, Koike K, Yasuda K, Milich DR. Serology of acute exacerbation in chronic hepatitis B virus infection. Gastroenterology 1993; 105: 1141– 1151.MEDLINE 58 Merkle H, Nusser P, Knehr S, Lohler J, Barsig J, Yamamura KI, Reifenberg K. Hepatocytes of double-transgenic mice expressing high levels of hepatitis B virus e antigen and interferon-gamma are not injured by HBeAg specific autoantibodies. Arch Virol 2000; 145: 1081– 1098.MEDLINE 59 Diepolder HM, Ries G, Jung MC, Schlicht HJ, Gerlach JT, Gruner N, Caselmann WH, et al. Differential antigen-processing pathways of the hepatitis B virus e and core proteins. Gastroenterology 1999; 116: 650– 657.MEDLINE 60 Franco A, Guidotti LG, Hobbs MV, Pasquetto V, Chisari FV. Pathogenetic effector function of CD4-positive T helper 1 cells in hepatitis B virus transgenic mice. J Immunol 1997; 159: 2001– 2008.MEDLINE 61 Chen M, Sallberg M, Thung SN, Hughes J, Jones J, Milich DR. Nondeletional T-cell receptor transgenic mice: model for the CD4(+) T-cell repertoire in chronic hepatitis B virus infection. J Virol 2000; 74: 7587– 7599.MEDLINE 62 Milich DR. Do T cells “see” the hepatitis B core and e antigens differently? Gastroenterology 1999; 116: 765– 768.MEDLINE 63 Kuhrober A, Wild J, Pudollek HP, Chisari FV, Reimann J. DNA vaccination with plasmids encoding the intracellular (HBcAg) or secreted (HBeAg) form of the core protein of hepatitis B virus primes T cell responses to two overlapping Kb- and Kd-restricted epitopes. Int Immunol 1997; 9: 1203– 1212.MEDLINE 64 Ni YH, Chang MH, Hsu HY, Chen HL. Long-term follow-up study of core gene deletion mutants in children with chronic hepatitis B virus infection. Hepatology 2000; 32: 124– 128.MEDLINE 65 Lok AS, Akarca U, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91: 4077– 4081.MEDLINE 66 Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K, Tanaka T, et al. Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen. J Virol 1994; 68: 8102– 8110.MEDLINE 67 Li J, Buckwold VE, Hon MW, Ou JH. Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation. J Virol 1999; 73: 1239– 1244.MEDLINE 68 Baumert TF, Marrone A, Vergalla J, Liang TJ. Naturally occurring mutations define a novel function of the hepatitis B virus core promoter in core protein expression. J Virol 1998; 72: 6785– 6795.MEDLINE 69 Chun YK, Kim JY, Woo HJ, Oh SM, Kang I, Ha J, Kim SS. No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection. Hepatology 2000; 32: 1154– 1162.MEDLINE 70 Honda A, Yokosuka O, Ehata T, Tagawa M, Imazeki F, Saisho H. Detection of mutations in the enhancer 2/core promoter region of hepatitis B virus in patients with chronic hepatitis B virus infection: comparison with mutations in precore and core regions in relation to clinical status. J Med Virol 1999; 57: 337– 344.MEDLINE 71 Hadziyannis SJ, Bramou T, Alexopoulou A, Makris A. Immunopathogenesis and natural course of anti-HBe positive chronic hepatitis with replicating B virus. In: FB Hollinger, SM Lemon, HS Margolis, eds. Viral Hepatitis and Liver Disease. Baltimore: Williams and Wilkins, 1991; 673– 676. 72 Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29– 60.MEDLINE 73 Perrillo RP. Acute Flares in Chronic Hepatitis B: The Natural and Unnatural History of an Immunologically Mediated Liver Disease. Gastroenterology 2001; 120: 1009– 1022.MEDLINE 74 Rehermann B. Intrahepatic T cells in hepatitis B: viral control versus liver cell injury. J Exp Med 2000; 191: 1263– 1268.MEDLINE 75 Hadziyannis SJ, Hadziyannis E, Georgiou A. HBV reactivation in anti-HBe positive HBsAg carriers [Abstract]. Hepatology 1992; 16: A64. 76 Lindh M, Horal P, Dhillon AP, Norkrans G. Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat 2000; 7: 258– 267.MEDLINE 77 Lohr HF, Schlaak JF, Gerken G, Fleischer B, Dienes HP, Meyer zBK. Phenotypical analysis and cytokine release of liver-infiltrating and peripheral blood T lymphocytes from patients with chronic hepatitis of different etiology. Liver 1994; 14: 161– 166.MEDLINE 78 Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999; 284: 825– 829.MEDLINE 79 Brunetto MR, Giarin MM, Oliveri F, Chiaberge E, Baldi M, Alfarano A, Serra A, et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A 1991; 88: 4186– 4190.MEDLINE 80 Lok AS, Hussain M, Cursano C, Margotti M, Gramenzi A, Grazi GL, Jovine E, et al. Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e antigen-negative patients receiving lamivudine therapy. Hepatology 2000; 32: 1145– 1153.MEDLINE 81 Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group. Hepatology 1999; 29: 889– 896.MEDLINE 82 Hamasaki K, Nakata K, Nagayama Y, Ohtsuru A, Daikoku M, Taniguchi K, Tsutsumi T, et al. Changes in the prevalence of HBeAg-negative mutant hepatitis B virus during the course of chronic hepatitis B. Hepatology 1994; 20: 8– 14.MEDLINE 83 Bonino F, Rosina F, Rizzetto M, Rizzi R, Chiaberge E, Tardanico R, Callea F, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986; 90: 1268– 1273.MEDLINE 84 Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Hepatology 1987; 7: 20– 23.MEDLINE 85 Brunetto MR, Oliveri F, Demartini A, Calvo P, Manzini P, Cerenzia MT, Bonino F. Treatment with interferon of chronic hepatitis B associated with antibody to hepatitis B e antigen. J Hepatol 1991; 13(Suppl 1): S8– 11.MEDLINE 86 Zarski JP, Marcellin P, Cohard M, Lutz JM, Bouche C, Rais A. Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France. French Multicentre Group. J Hepatol 1994; 20: 636– 640.MEDLINE 87 Tur-Kaspa R, Klein A, Aharonson S. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity. Hepatology 1992; 16: 1338– 1342.MEDLINE 88 Hadziyannis SJ, Hadziyannis AS, Dourakis S, Alexopoulou A, Horsch A, Hess G. Clinical significance of quantitative anti-HBc IgM assay in acute and chronic HBV infection. Hepatogastroenterology 1993; 40: 588– 592.MEDLINE 89 Brunetto MR, Cerenzia MT, Oliveri F, Piantino P, Randone A, Calvo PL, Manzini P, et al. Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc. J Hepatol 1993; 19: 431– 436.MEDLINE 90 Marinos G, Smith HM, Naoumov NV, Williams R. Quantitative assessment of serum IgM anti-HBc in the natural course and during interferon treatment of chronic hepatitis B virus infection. Hepatology 1994; 19: 303– 311.MEDLINE 91 Colloredo G, Bellati G, Leandro G, Colombatto P, Rho A, Bissoli F, Brunetto MR, et al. Quantitative analysis of IgM anti-HBc in chronic hepatitis B patients using a new “gray-zone” for the evaluation of “borderline” values. J Hepatol 1996; 25: 644– 648.MEDLINE 92 Zavaglia C, Mondazzi L, Maggi G, Iamoni G, Gelosa F, Bellati G, Colloredo G, et al. Are alanine aminotransferase, hepatitis B virus DNA or IgM antibody to hepatitis B core antigen serum levels predictors of histological grading in chronic hepatitis B? Liver 1997; 17: 83– 87.MEDLINE 93 Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y, Tsuda F, et al. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol 1990; 64: 1298– 1303.MEDLINE 94 Liaw YF, Chu CM, Su IJ, Huang MJ, Lin DY, Chang-Chien CS. Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology 1983; 84: 216– 219.MEDLINE 95 Liaw YF, Huang MJ, Chu CM, Sheen IS, Lin DY. The window period between hepatitis B e antigen and antibody in chronic type hepatitis. Hepatology 1984; 4: 619– 621.MEDLINE 96 Lok AS, Hadziyannis SJ, Weller IV, Karvountzis MG, Monjardino J, Karayiannis P, Montano L, et al. Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection. Gut 1984; 25: 1283– 1287.MEDLINE 97 Su IJ, Lai MY, Hsu HC, Chen DS, Yang PM, Chuang SM, Sung JL. Diverse virological, histopathological and prognostic implications of seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. J Hepatol 1986; 3: 182– 189.MEDLINE 98 Tong MJ, Sampliner RE, Govindarajan S, Co RL. Spontaneous reactivation of hepatitis B in Chinese patients with HBsAg-positive chronic active hepatitis. Hepatology 1987; 7: 713– 718.MEDLINE 99 Raimondo G, Schneider R, Stemler M, Smedile V, Rodino G, Will H. A new hepatitis B virus variant in a chronic carrier with multiple episodes of viral reactivation and acute hepatitis. Virology 1990; 179: 64– 68.MEDLINE 100 Laskus T, Rakela J, Tong MJ, Persing DH. Nucleotide sequence analysis of the precore region in patients with spontaneous reactivation of chronic hepatitis B. Dig Dis Sci 1994; 39: 2000– 2006.MEDLINE 101 Koike K, Iino S, Kurai K, Mitamura K, Endo Y, Oka H. IgM anti-HBc in anti-HBe positive chronic type B hepatitis with acute exacerbations. Hepatology 1987; 7: 573– 576.MEDLINE 102 Gupta S, Govindarajan S, Fong TL, Redeker AG. Spontaneous reactivation in chronic hepatitis B: patterns and natural history. J Clin Gastroenterol 1990; 12: 562– 568.MEDLINE 103 Zhong S, Chan JY, Yeo W, Tam JS, Johnson PJ. Frequent integration of precore/core mutants of hepatitis B virus in human hepatocellular carcinoma tissues. J Viral Hepat 2000; 7: 115– 123.MEDLINE 104 Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberge E, Capalbo M, David E, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989; 10: 198– 202.MEDLINE 105 Hadziyannis S, Alexopoulou A, Papakonstantinou A, Petraki K, Manesis E. Interferon treatment with or without oral ganciclovir in HBeAg-negative chronic hepatitis B: a randomized study. J Viral Hepat 2000; 7: 235– 240.MEDLINE 106 Oliveri F, Santantonio T, Bellati G, Colombatto P, Mels GC, Carriero L, Dastoli G, et al. Long term response to therapy of chronic anti-HBe-positive hepatitis B is poor independent of type and schedule of interferon. Am J Gastroenterol 1999; 94: 1366– 1372.MEDLINE 107 Manesis EK, Hadziyannis SJ. Interferon-alpha treatment and re-treatment of hepatitis B e antigen negative chronic hepatitis B. Gastroenterology 2001; 121: 101– 109.MEDLINE 108 Alexopoulou A, Zafiropoulou R, Papakonstontinou A, Hadziyannis SJ. Randomised trial in hepatitis B e antigen negative patients with replicating virus with ganciclovir vs lamivudine in combination with IFN-a. Evaluation of long-term efficacy [Abstract]. Hepatology 1998; 28: 490A. 109 Rizzetto M, Santantonio T, Heathcote EJ, Woessner M, Daly S, Stephenson S, Dent JC, et al. Benefits of extended lamivudine treatment in patients with HBeAg-negative HBV DNA-positive (pre-core mutant) chronic hepatitis B [Abstract]. Hepatology 2000; 32: 459A. 110 Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, Johnson M, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000; 32: 1078– 1088.MEDLINE 111 Papatheodoridis GV, Dimou E, Rapti I, Papadimitropoulos V, Alexopoulou A, Laras A, Hadziyannis SJ. HBV reactivation and biochemical breakthroughs after initially effective lamivudine therapy in patients with precore mutant HBV related liver disease [Abstract]. Hepatology 2000; 32: 375A. 112 Laras A, Karayiannis P, Spanou F, Koskinas J, Hadziyannis SJ. In vivo suppression of precore mRNA synthesis from the hepatitis B virus core promoter in patients with chronic hepatitis B [Abstract]. Hepatology 2000; 32: 449A. 113 Cho SW, Hahm KB, Kim JH. Reversion from precore/core promoter mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000; 32: 1163– 1169.MEDLINE 114 Torresi J, Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000; 118: S83– 103.MEDLINE Citing Literature Volume34, Issue4October 2001Pages 617-624 ReferencesRelatedInformation" @default.
• W2119612879 created "2016-06-24" @default.
• W2119612879 creator A5049183697 @default.
• W2119612879 date "2001-10-01" @default.
• W2119612879 modified "2023-10-18" @default.
• W2119612879 title "Hepatitis B e antigen–negative chronic hepatitis B" @default.
• W2119612879 cites W1498132922 @default.
• W2119612879 cites W1499192344 @default.
• W2119612879 cites W1581971337 @default.
• W2119612879 cites W1594706749 @default.
• W2119612879 cites W1608204833 @default.
• W2119612879 cites W1690683413 @default.
• W2119612879 cites W1813446025 @default.
• W2119612879 cites W1815340666 @default.
• W2119612879 cites W1859239181 @default.
• W2119612879 cites W1887371688 @default.
• W2119612879 cites W1940739348 @default.
• W2119612879 cites W1963623444 @default.
• W2119612879 cites W1965074477 @default.
• W2119612879 cites W1966113174 @default.
• W2119612879 cites W1968760089 @default.
• W2119612879 cites W1970493256 @default.
• W2119612879 cites W1971803726 @default.
• W2119612879 cites W1972113563 @default.
• W2119612879 cites W1974706615 @default.
• W2119612879 cites W1976380567 @default.
• W2119612879 cites W1977860156 @default.
• W2119612879 cites W1979010048 @default.
• W2119612879 cites W1979903974 @default.
• W2119612879 cites W1981885989 @default.
• W2119612879 cites W1983104590 @default.
• W2119612879 cites W1983757435 @default.
• W2119612879 cites W1984835306 @default.
• W2119612879 cites W1987947802 @default.
• W2119612879 cites W1992194872 @default.
• W2119612879 cites W2002726058 @default.
• W2119612879 cites W2004837207 @default.
• W2119612879 cites W2006368736 @default.
• W2119612879 cites W2008573155 @default.
• W2119612879 cites W2009857602 @default.
• W2119612879 cites W2010145433 @default.
• W2119612879 cites W2010621350 @default.
• W2119612879 cites W2011862847 @default.
• W2119612879 cites W2012912732 @default.
• W2119612879 cites W2016600332 @default.
• W2119612879 cites W2018479084 @default.
• W2119612879 cites W2027479395 @default.
• W2119612879 cites W2031500470 @default.
• W2119612879 cites W2035845537 @default.
• W2119612879 cites W2038655590 @default.
• W2119612879 cites W2041473358 @default.
• W2119612879 cites W2052968140 @default.
• W2119612879 cites W2059667737 @default.
• W2119612879 cites W2059753275 @default.
• W2119612879 cites W2060576232 @default.
• W2119612879 cites W2065600861 @default.
• W2119612879 cites W2065744702 @default.
• W2119612879 cites W2069378061 @default.
• W2119612879 cites W2074439314 @default.
• W2119612879 cites W2076070180 @default.
• W2119612879 cites W2084720260 @default.
• W2119612879 cites W2085690205 @default.
• W2119612879 cites W2086286242 @default.
• W2119612879 cites W2086456107 @default.
• W2119612879 cites W2088928592 @default.
• W2119612879 cites W2092592271 @default.
• W2119612879 cites W2095853007 @default.
• W2119612879 cites W2096212331 @default.
• W2119612879 cites W2096869260 @default.
• W2119612879 cites W2097375253 @default.
• W2119612879 cites W2098478904 @default.
• W2119612879 cites W2105524736 @default.
• W2119612879 cites W2107704647 @default.
• W2119612879 cites W2108308364 @default.
• W2119612879 cites W2108718620 @default.
• W2119612879 cites W2109619534 @default.
• W2119612879 cites W2118434108 @default.
• W2119612879 cites W2120128540 @default.
• W2119612879 cites W2124753560 @default.
• W2119612879 cites W2128721549 @default.
• W2119612879 cites W2128932565 @default.
• W2119612879 cites W2131193659 @default.
• W2119612879 cites W2132977171 @default.
• W2119612879 cites W2133423537 @default.
• W2119612879 cites W2134783987 @default.
• W2119612879 cites W2136425954 @default.
• W2119612879 cites W2138406643 @default.
• W2119612879 cites W2138413826 @default.
• W2119612879 cites W2140679976 @default.
• W2119612879 cites W2141044770 @default.
• W2119612879 cites W2142331199 @default.
• W2119612879 cites W2142338711 @default.
• W2119612879 cites W2143345692 @default.
• W2119612879 cites W2144297979 @default.
• W2119612879 cites W2145782156 @default.
• W2119612879 cites W2149603246 @default.
• W2119612879 cites W2150556371 @default.
• W2119612879 cites W2151376250 @default.

• next